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Background: Prostate cancer cell growth is dependent upon androgen receptor (AR) activation, which is regulated by specific
kinases. The aim of the current study is to establish if AR phosphorylation by Cdk1 or ERK1/2 is of prognostic significance.
Methods: Scansite 2.0 was utilised to predict which AR sites are phosphorylated by Cdk1 and ERK1/2. Immunohistochemistry for
these sites was then performed on 90 hormone-naive prostate cancer specimens. The interaction between Cdk1/ERK1/2 and AR
phosphorylation was investigated in vitro using LNCaP cells.
Results: Phosphorylation of AR at serine 515 (pARS515) and PSA at diagnosis were independently associated with decreased time
to biochemical relapse. Cdk1 and pCdk1161, but not ERK1/2, correlated with pARS515. High expression of pARS515 in patients with a
PSA at diagnosis of p20 ngml 1 was associated with shorter time to biochemical relapse (P¼ 0.019). This translated into a
reduction in disease-specific survival (10-year survival, 38.1% vs 100%, Po0.001). In vitro studies demonstrated that treatment with
Roscovitine (a Cdk inhibitor) caused a reduction in pCdk1161 expression, pARS515expression and cellular proliferation.
Conclusion: In prostate cancer patients with PSA at diagnosis ofp20 ngml 1, phosphorylation of AR at serine 515 by Cdk1 may
be an independent prognostic marker.
An estimated 899 000 men were diagnosed with prostate cancer
worldwide in 2008 with most cases in developed countries (Ferlay
et al, 2010). Incidence is increasing and expected to rise 69% by
2030 in the United Kingdom (Mistry et al, 2011). Prostate cancer
therefore represents a considerable economic burden. Treatment
decision-making in prostate cancer is increasing in complexity, but
in general patients with PSAo20 ngml 1 at diagnosis are offered
immediate or delayed radical treatment dependent on life
expectancy, biopsy result and imaging. However, not all patients
harbour disease that requires treatment. Conversely, some patients
undergo treatment delay following a period of surveillance creating
an opportunity for occult aggressive disease to progress. Currently,
there are no reliable diagnostic tools to differentiate indolent from
aggressive cancers. This results in both over- and under-treatment
problems with consequent patient-related morbidity and mortality
and substantial economic cost.
The molecular mechanisms underlying the natural history of
prostate cancer remain elusive. However, it is accepted that
prostate cancer cell growth and survival are exquisitely dependent
upon activation of the androgen receptor (AR) by androgens.
www.bjcancer.com |DOI:10.1038/bjc.2012.480 139
*Correspondence: Dr J Edwards; E-mail: joanne.edwards@glasgow.ac.uk
6Willder and Heng are joint first authors.
Received 11 June 2012; revised 30 August 2012; accepted 27 September 2012; published online 4 December 2012
& 2013 Cancer Research UK. All rights reserved 0007 – 0920/13
FULL PAPER
Keywords: androgen receptor; biomarker; phosphorylation; prostate cancer
British Journal of Cancer (2013) 108, 139–148 | doi: 10.1038/bjc.2012.480
Following ligand binding, AR undergoes further phosphorylation
at serine residues (Kuiper and Brinkmann, 1995; Gioeli and
Paschal, 2012). Such phosphorylation is thought to inhibit
proteolytic degradation and stabilise AR homodimers (Blok et al,
1998). Phosphorylation of AR may also influence transactivation of
the AR since AR transcriptional activity correlates strongly with
phosphorylation of specific serine residues (Blok et al, 1998).
Phosphorylation may be seen as a mechanism that generates
changes within the specific domains that affect AR function.
Although each of the major AR domains contains at least one
phosphorylation site, the majority are located in the N-terminal
domain (NTD), which is important for AR transactivation,
including Ser-81, Ser-94, Ser-308 and Ser-515 (Gioeli and
Paschal, 2012). In addition, Ser-650 is located in the hinge region,
which regulates nuclear localisation, DNA binding and co-activator
recruitment (Zhou et al, 1995; Gioeli et al, 2006; Gioeli and
Paschal, 2012). Androgen receptor Ser-515 phosphorylation in
particular has been linked to nuclear-cytoplasmic shuttling
(Ponguta et al, 2008), while Ser-81 phosphorylation has been
shown to mediate chromatin binding and transcriptional activation
(Chen et al, 2012). It is therefore plausible that alterations in AR
phosphorylation may drive prostate carcinogenesis. However, few
studies have explored the significance of AR phosphorylation in
prostate cancer in the clinical setting.
Several kinases have been associated with established AR
phosphorylation (Zhou et al, 1995; Wong et al, 2004; Gioeli and
Paschal, 2012). In particular, cyclin-dependent kinase 1 (Cdk1) and
the mitogen-activated protein kinases also known as extracellular
signal regulated kinase 1 and 2 (ERK1/2) have been associated with
AR phosphorylation at various serine sites (Chen et al, 2006;
Shigemura et al, 2009; Gioeli and Paschal, 2012). However,
conflicting data exists over the responsible kinase(s) and functional
consequences of phosphorylation at each site. Upregulation of the
ERK1/2 pathway has been associated with development of castrate-
resistant prostate cancer and reduced disease-specific survival
(Mukherjee et al, 2011). ERK1/2-induced phosphorylation of the
AR at serine 515 has been demonstrated to hyper-sensitise LNCaP
cells to low levels of synthetic androgens, increase AR transactiva-
tion, facilitate recruitment of AR cofactors and increase prostate
cancer cell growth (Bakin et al, 2003). Cdk1 is reported to be
upregulated in prostate cancer tissue (Kallakury et al, 1997) and
phosphorylation of AR at serine 81 in vitro by Cdk1 is associated
with prevention of AR degradation, thereby increasing AR stability
and resulting in increased AR protein expression (Chen et al,
2006). However, cell line studies that investigated mutagenesis at
serine 81 indicate that phosphorylation at this site alone does not
drive AR transcriptional activity or stabilisation, suggesting that
Cdk1 may mediate these effects on the AR through phosphoryla-
tion at multiple sites (Zhou et al, 1995; Chen et al, 2006; Gioeli
et al, 2006).
In the current study, we aim to determine whether AR
phosphorylation at Cdk1 and ERK1/2 consensus sites is associated
with clinico-pathologic parameters and outcome in a cohort of
hormone-naive prostate cancer patients. It is hypothesised that AR
phosphorylation at certain sites may be associated with disease
progression and the knowledge of such may help to inform
treatment decision-making.
MATERIALS AND METHODS
Patients. Ninety patients with hormone-naive prostate cancer
samples available were recruited at the Glasgow Royal Infirmary
between 1992 and 2002. Last date of follow-up was 11/01/2012.
Patients gave written consent. Clinical data included age, Gleason
score, tumour lymphovascular invasion (LVI), serum PSA levels at
diagnosis, biochemical recurrence, serum PSA at biochemical
recurrence and presence of metastases. Patients were considered to
have biochemical recurrence dependent on treatment; radical
prostatectomy serum PSA 40.2 ngml 1, radical radiotherapy
serum PSA of 2.0 ngml 1 above the post-treatment nadir level,
hormone treatment 2–3 consecutive rises in serum PSA levels
above the nadir obtained at intervals of 42 weeks (Roach et al,
2006; Cookson et al, 2007). Study end points were biochemical
relapse, survival from biochemical relapse and disease-specific
survival. West of Scotland Research Ethics Committee approved
the study (reference: 05/S0704/94).
Identification of kinases mediating AR phosphorylation. Scan-
site 2.0 was utilised to predict which sites on the AR would be
phosphorylated by Cdk1 and ERK1/2 (Obenauer et al, 2003). The
search was conducted using the protein ID ‘ANDR_HUMAN’
(accession number: P10275).
Tissue microarray construction. Three 0.6mm2 cores of prostate
cancer tissue, identified by a uropathologist, were removed from
formalin-fixed paraffin-embedded blocks. Recipient array blocks
were constructed in triplicate. Control cores of normal prostate,
colon, breast, pancreas, tonsil, kidney, liver and lung tissue were
included in each tissue microarray (TMA).
Immunohistochemistry. Immunohistochemistry (IHC) was con-
ducted in triplicate on aforementioned TMAs for the following
proteins: Cdk1, Cdk1 activated through Thr-161 (pCdk1161)
phosphorylation, ERK1/2 activated through Thr-202 and Tyr-204
(pERK1202/204) or Thr-185 and Tyr-187 (pERK2185/187) phosphor-
ylation, Ki67 (proliferation index), AR and AR phosphorylated at
Ser-81 (pARS81), Ser-94 (pARS94), Ser-308 (pARS308), Ser-515
(pARS515) and Ser-650 (pARS650). Tissue microarrays were
dewaxed in xylene and rehydrated through graded alcohol. The
AR antigen retrieval was performed in DakoCytomation Target
Retrieval Solution (Dako UK Ltd., Ely, UK) pre-heated water bath,
99 1C, 20min. pERK1/2 antigen retrieval was performed in pH9
Tris-EDTA buffer (10mM Trizma Base, 0.25mM EDTA), 96 1C,
20min. Ki67 antigen retrieval was performed using heat treatment
under pressure in citrate buffer pH 6, 5min. Antigen retrieval for
remaining proteins was performed using heat treatment under
pressure in Tris-EDTA buffer (5mM Trizma Base, 1mM EDTA,
pH 8), 5min. Sections cooled in buffer for 20min before washing
in 3% H2O2. Sections blocked using 5% horse serum (10% casein
for pERK1/2) in Tris-buffered saline (TBS). Antibodies for Cdk1
(#ab18; Abcam, Cambridge, UK), pARS308 (#sc-26406-R; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) and Ki67 (#F0788;
Dako UK Ltd.) were incubated for 1 h, 25 1C diluted at 1 : 200, 1 : 75
and 1 : 150, respectively. Antibodies for pCdk1161 (#ab47329;
Abcam), pERK1/2 (pERK1202/204, pERK2185/187) (#9101; Cell
Signaling Technology Inc., Danvers, MA, USA), AR (#M3562;
Dako UK Ltd.), pARS81 (#07-1375; Merk Millipore, Billerica, MA,
USA), pARS94 (#ab62205; Abcam), pARS515 (Protein sequence
MVSRVPYP-S(PO3H2)-PTCV, raised in rabbit by Eurogentec
Ltd., Southampton, UK) and pARS650 (#ab47563-100; Abcam)
were incubated overnight at 4 1C diluted at 1 : 50, 1 : 100, 1 : 100,
1 : 1000, 1 : 25, 1 : 500 and 1 : 100, respectively. All antibodies
diluted in Dako antibody diluent (Dako UK Ltd.). Bound antibody
complex visualised using EnVision plus kit (#K5007; Dako UK
Ltd.) followed by 3,3-diaminobenzidine tetrahydrochloride (DAB,
Dako UK Ltd.). Nuclei were counterstained with haematoxylin and
Scots Tap Water Substitute, dehydrated through graded alcohol
and xylene and mounted with Di-N-Butyl Phthalate in xylene.
Antibody validation. Peptide competition assays were performed
to confirm antibody specificity for each AR serine phosphorylation
site. pARS308 (#sc-26406-P; Santa Cruz Biotechnology Inc.) peptide
was incubated at a ratio of 3 : 1 for 1 h with each antibody. pARS81
(Protein sequence QQQQQQET(pS)PRQQ raised in rabbit by
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EZbiolab Inc., Carmel, IN, USA), pARS94 (Protein sequence
QQQQQGEDG(pS)PQAH raised in rabbit by EZbiolab Inc.),
pARS515 (Protein sequence MVSRVPYP-S(pS)-PTCV raised in
rabbit by Eurogentec Ltd.) and pARS650 (Protein sequence
EEGEASSTT(pS)PTEE raised in rabbit by EZbiolab Inc.) peptides
were incubated at ratios of 1 : 1, 2 : 1, 500 : 1 and 100 : 1,
respectively, with each antibody overnight at 4 1C. Immunohis-
tochemistry was then performed as described above and results are
shown in Supplementary data.
Scoring. Tissue staining intensity was scored by two blinded
independent observers using a weighted histo-score (H-score)
method (McCarty et al, 1986; Kirkegaard et al, 2006). H-score was
calculated from the formula: (0% cells staining negative)þ (1
% cells staining weakly positive)þ (2% cells staining moder-
ately positive)þ (3% cells staining strongly positive). The mean
H-score from staining conducted in triplicate was used for analysis.
Western blotting. Cells were lysed in radioimmunoprecipitation
assay buffer and Roche protease inhibitor cocktail set one. Lysates
were centrifuged at 14 000 r.p.m. for 15min at 4 1C, supernatant
removed and protein concentration determined using Bradford’s
assay (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). In all,
50 mg of protein per well was resolved by 10% SDS–PAGE and
transferred onto PVDF membranes (Bio-Rad Laboratories Ltd.).
Membranes were blocked for 1 h in 5% non-fat milk in TTBS
(1TBS and 0.1% Tween-20) and probed with primary antibodies
at 4 1C overnight. Membranes were incubated with secondary
antibodies (Cell Signaling Technology, Inc.) and visualised with
ECL plus kit (Fisher Scientific UK Ltd., Loughborough, UK).
Membranes were stripped by incubating with Re-Blot Plus
stripping buffer (Merk Millipore) then incubated with ECL plus
kit to ensure complete stripping. The membranes were then
blocked for 1 h in 5% non-fat milk in TTBS (1TBS and 0.1%
Tween-20) and probed with anti-Tubulin (Abcam) to confirm
equal protein loading.
Cdk1 inhibition. Inhibitor studies were conducted to determine
whether endogenous Cdk1 mediates AR phosphorylation in
prostate cancer cells. LNCaP cells were treated with Roscovitine
(20 mM), a selective inhibitor of cellular Cdks (Cdk1, Cdk2 and
Cdk5) for 24 h or dihydrotestosterone (DHT) (10 nM) for 3 h. Cells
were trypsinised and collected by centrifugation at 1200 r.p.m. The
supernatant was discarded and pellets were washed in HBSS. Cells
were fixed in 4% formalin, briefly vortexed and rested at room
temperature for 15min. Cells were then centrifuged at 2500 r.p.m.
for 3min, the supernatant discarded and then washed in HBSS.
Cells were set in 1% agarose at 4 1C for 1 h. Cell pellets were
dehydrated through graded alcohol and xylene and embedded into
paraffin blocks. Immunohistochemistry was performed as
described (antigen retrieval reduced to 2.5min) for protein
expression of pCdk1161, pARS81, pARS515 and Ki67.
Statistical analysis. Statistical analysis was performed using SPSS
version 19.0 for Windows (IBM, Armonk, NY, USA). Intra-class
correlation coefficients (ICCCs) confirmed histo-scoring consis-
tency between observers. Pearson’s rank correlation coefficients
(CC) assessed associations between protein expression. Mann–
Whitney U-test or Kruskal–Wallis test assessed relationships
between protein expression and clinico-pathologic characteristics.
Kaplan–Meier methods, using the log-rank test, compared survival
between patients according to clinico-pathologic parameters and
high/low protein expression. Significant univariate results were
included in a backwards conditional cox-regression model to
determine independence from current clinical parameters. A
o0.05 significance level was used and Bonferroni correction was
used where applicable.
RESULTS
Patient characteristics. Analysis was based on 90 hormone-naive
prostate cancer patients. Patient characteristics are shown in
Table 1. Twenty-three patients had metastases to local lymph
nodes (3), bone (13) and at both sites (7).
Forty-seven patients had biochemical relapse (median time to
biochemical relapse 2.7 years, interquartile range 1.5–3.8). Twenty-
four patients were alive at the time of analysis, median follow-up
was 11.7 years (interquartile range 9.9–14.0). Forty-six died of their
disease (median time to death 4 years, interquartile range 1.9–7.2)
and twenty deaths were attributed to intercurrent disease (median
time to death 4.1 yr, interquartile range 0.9–5.5). Table 2 shows
associations with clinical parameters (grouped data) and outcome
measures using Kaplan–Meier methods.
Protein expression analysis. Expression of all proteins was
observed at varying levels in the cytoplasm and nucleus of both
stromal and epithelial cells (Figure 1). Protein expression was
found to be heterogeneous throughout and less intense in the
stromal cells. There was presence of PIN and benign tissue,
adjacent to the neoplastic tissue, in some of the TMA cores.
Expression of proteins in the interspersed PIN and benign tissue
and the normal prostate control core was heterogeneous and less
intense than the neoplastic tissue. Only protein expression
observed in the tumour cells was scored. All ICCC values were
40.80. Protein expression levels were subdivided into low
(pmedian) and high expression (4median) for analysis.
Association between protein expression and clinico-pathologic
outcome measures
AR and AR phosphorylated at serine residues. High expression of
pARS81 (cytoplasmic), pARS515 (nuclear and total) and pARS650
(cytoplasmic, nuclear and total) was associated with increased age
(Table 3A). High expression of nuclear pARS308 was associated
Table 1. Cohort characteristics
Clinical parameter Percentage of patients (%)
Age (years)
o70 37.8
X70 62.2
Gleason
o7 31.2
¼7 32.5
47 36.4
PSA at diagnosis
o10 ngml 1 27.5
10–20 ngml 1 20.3
420ngml1 52.2
Lymphovascular invasion
Absence 93.3
Presence 6.7
Recurrence PSA
o10 ngml 1 77.6
10–20 ngml 1 2.0
420ngml1 20.4
Abbreviation: PSA¼prostate specific antigen.
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with increased PSA level at diagnosis. Presence of LVI was
associated with high AR (nuclear, cytoplasmic and total) and
pARS515 (cytoplasmic) expression. Presence of metastases was
associated with high AR (total) and pARS515 (cytoplasmic)
expression. High expression of pARS81 (nuclear and total) and
low expression of pARS94 (cytoplasmic) were associated with high
Ki67 score (4median) (Table 3A).
Candidate kinases. High total pCdk1161 expression was associated
with increased age (Table 3B). High expression of pCdk1161
(nuclear and total) was associated with increased PSA level at
relapse. Conversely, high nuclear pERK1/2 expression was
associated with low Ki67 score (pmedian) (Table 3B).
Kinases mediating AR phosphorylation. Scansite 2.0 predicted
Cdk1 and ERK1/2 as strong candidates mediating phosphorylation
of Ser-81, Ser-94, Ser-308, Ser-515 and Ser-650. In the clinical
specimens, pERK1/2 expression was not associated with any
of the candidate AR phosphorylation sites; however, Cdk1 and
pCdk1161 were significantly associated with pARS81 and pARS515
(Table 4).
Associations observed between protein expression and time to
biochemical relapse. No associations were observed between the
kinases and time to biochemical relapse; however, high nuclear AR
was associated with biochemical relapse (proportion of patients
relapsed at 5 years 79.2% vs 46.9%) HR 2.8 (95% CI 1.5–5.3),
P¼ 0.001, as was high total AR (proportion of patients relapsed at
5 years 85.1% vs 40.2%) HR 3.03 (95% CI 1.6–5.6), Po0.001. High
cytoplasmic pARS515 was also associated with biochemical relapse
(proportion of patients relapsed at 5 years 78.6% vs 56%) HR 2.15
(95% CI 1.1–4.2), P¼ 0.02 (Table 5).
Table 2. Relationship between clinical parameters and clinical outcome measures
Time to
biochemical relapse
Survival from
biochemical relapse
Disease-specific
survival
Age (o70 vs X70 years) 0.260 0.385 0.020
Gleason (o7 vs ¼7 vs 47) 0.013 0.754 0.008
Diagnosis PSA (o10 vs 10–20 vs 420 ngml 1) 0.002 0.078 0.001
Recurrence PSA (o10 vs 10–20 vs 420ngml1) o0.001 o0.001
Lymphovascular invasion (presence vs absence) 0.001 0.612 0.114
Presence of metastases (presence vs absence) 0.001 0.008 o0.001
Ki67 (pmedian vs 4median) 0.730 0.279 0.033
Abbreviation: PSA¼prostate specific antigen.
The clinical variables were grouped and analysed by Kaplan–Meier methods with reference to clinical outcome measures as shown.
Patients were considered to have biochemical relapse dependent on treatment; radical prostatectomy serum PSA40.2 ngml 1, radical radiotherapy serum PSA of 2.0 ngml 1 above the post-
treatment nadir level, hormone treatment 2–3 consecutive rises in serum PSA levels above the nadir obtained at intervals of 42 weeks (Roach et al, 2006; Cookson et al, 2007).
Numbers in bold denote significant associations with P-value o0.05.
AR (low) AR (high)
pARS81 (low)
pARS94 (low)
pARS81 (high)
pARS94 (high)
pARS308 (low)
pARS515 (low)
pARS650 (low) pARS650 (high)
pARS515 (high)
pARS308 (high)
Figure 1. Image illustrating high (4median histoscore) and low (pmedian histoscore) intensity immunohistochemical staining for androgen
receptor (AR) and AR phosphorylated at Ser-81 (pARS81), 94 (pARS94), 308 (pARS308), 515 (pARS515) and 650 (pARS650) ( 10 magnification).
Intra-class correlation coefficients (ICCCs) confirmed histoscoring consistency between two independent observers and all ICCC values were
40.80.
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Table 3. (A) Associations between clinical variables and androgen receptor phosphorylation sites. (B) Associations between clinical variables and
candidate kinases
Clinical variables
Proteins
Age
(o70 vs
X70 years)
Gleason
(o7 vs ¼7
vs 47)
Diagnosis PSA
(o10 vs 10–20
vs 420ngml 1
Recurrence PSA
(o10 vs 10–20
vs 420ngml1)
Lymphovascular
invasion (presence
vs absence)
Presence of
metastases
(presence vs absence)
Ki67
(pmedian
vs 4median)
A
AR
Cytoplasm 0.909 0.841 0.979 0.496 0.028 0.061 0.230
Nucleus 0.284 0.450 0.301 0.380 0.006 0.107 0.154
Total 0.422 0.464 0.493 0.800 0.002 0.027 0.627
pARS81
Cytoplasm 0.035 0.811 0.269 0.566 0.175 0.660 0.498
Nucleus 0.651 0.401 0.462 0.601 0.666 0.229 0.039
Total 0.220 0.425 0.389 0.632 0.290 0.195 0.041
pARS94
Cytoplasm 0.447 0.714 0.437 0.820 0.234 0.165 0.040
Nucleus 0.651 0.069 0.726 0.386 0.234 0.892 0.361
Total 0.754 0.417 0.964 0.496 0.864 0.554 0.191
pARS308
Cytoplasm 0.169 0.567 0.441 0.848 0.386 0.656 0.662
Nucleus 0.854 0.324 0.049 0.413 0.836 0.601 0.284
Total 0.515 0.651 0.109 0.375 0.769 0.906 0.531
pARS515
Cytoplasm 0.221 0.109 0.181 0.273 0.018 0.040 0.233
Nucleus 0.042 0.336 0.052 0.116 0.673 0.948 0.156
Total 0.048 0.120 0.287 0.120 0.463 0.528 0.229
pARS650
Cytoplasm 0.046 0.446 0.976 0.761 0.773 0.750 0.260
Nucleus 0.018 0.531 0.169 0.935 0.279 0.216 0.756
Total 0.020 0.465 0.216 0.827 0.516 0.447 0.504
B
Cdk1
Cytoplasm 0.320 0.259 0.741 0.129 0.232 0.690 0.436
Nucleus 0.665 0.898 0.255 0.464 0.563 0.353 0.838
Total 0.187 0.831 0.277 0.130 0.583 0.432 0.879
pCdk1161
Cytoplasm 0.165 0.929 0.091 0.298 0.640 0.192 0.494
Nucleus 0.084 0.255 0.164 0.047 0.389 0.259 0.630
Total 0.044 0.263 0.108 0.017 0.621 0.204 0.918
pERK1/2
Cytoplasm 0.293 0.175 0.854 0.639 0.471 0.180 0.530
Nucleus 0.908 0.329 0.990 0.152 0.147 0.674 0.033
Total 0.315 0.555 0.936 0.569 0.160 0.428 0.280
Abbreviations: AR¼ androgen receptor; PSA¼prostate-specific antigen.
Cytoplasmic, nuclear and total (cytoplasmicþnuclear) expression of androgen receptor and phosphorylated androgen receptor (A) and candidate kinases (Cdk1, pCdk1161 and pERK1/2) (B)
were examined for significant relationships with clinical variables as shown.
Protein expression scores were used and clinical variables were divided into groups.
When the clinical variable consisted of two independent groups the Mann–Whitney U-test was performed, and 42 independent groups the Kruskal–Wallis test was used.
Significant associations are highlighted in bold.
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Associations observed between protein expression and survival
from biochemical relapse. Survival from biochemical relapse was
calculated from biochemical relapse till death or last follow-up
using cancer-specific deaths. High cytoplasmic Cdk1 was asso-
ciated with survival from biochemical relapse (10-year survival
12.1% vs 48.9%) HR 2.9 (95% CI 1.2–6.3), P¼ 0.011. High nuclear
pCdk1161 was associated with survival from biochemical relapse
(10-year survival 29.2% vs 51.4%) HR 3.18 (95% CI 1.1–9.3),
P¼ 0.026 (Table 5). High cytoplasmic pARS515 was associated with
survival from biochemical relapse (10-year survival 15.6% vs
55.5%) HR 2.9 (95% CI 1.2–7.1), P¼ 0.016 (Table 5).
Associations observed between biomarkers and disease-specific
survival. Disease-specific survival was calculated from diagnosis
till death or last follow-up using cancer-specific deaths. High
cytoplasmic Cdk1 was associated with disease-specific survival (10-
year survival 26.8% vs 57.2%) HR 2.4 (95% CI 1.2–4.5), P¼ 0.007.
High cytoplasmic pCdk1161 was associated with disease-specific
survival (10-year survival 29.8% vs 58.3%) HR 2.5 (95% CI 2.5–
5.4), P¼ 0.013. High nuclear pCdk1161 was associated with disease-
specific survival (10-year survival 27.8% vs 67.9%) HR 3.7 (95% CI
1.6–8.5), P¼ 0.001 (Table 5). High total pCdk1161 was associated
with disease-specific survival (10-year survival 30.6% vs 64.4%)
HR 2.9 (95% CI 1.3–6.4), P¼ 0.007. High nuclear pARS81 was
associated with disease-specific survival (10-year survival 24.4% vs
54.5%), HR 2.112 (95% CI 1.1–4.2), P¼ 0.031. High total pARS81
was associated with disease-specific survival (10-year survival
25.6% vs 56.5%), HR 2.0 (95% CI 1.0–4.1), P¼ 0.039. High
cytoplasmic pARS515 was associated with disease-specific survival
(10-year survival 14.4% vs 65.2%) HR 4.4 (95%CI 2.1–9.1),
P¼ 1.54 10 5 (Table 5). High total pARS515 was associated with
disease-specific survival (10-year survival 35.8% vs 57.5%), HR 2.1
(95% CI 1.0–4.2), P¼ 0.034.
Multivariate cox-regression analysis to determine if biomarkers
are able to independently predict time to biochemical relapse.
Expression of AR and pARS515 was combined with Gleason score,
PSA at diagnosis, LVI and presence of metastases in multivariate
analysis. Cytoplasmic pARS515 expression (P¼ 0.038, HR 4.5 (95%
CI 1.1–20.6)) and PSA at diagnosis (P¼ 0.003, HR 7.3 (95% CI
2.0–27.5)) were independently associated with time to biochemical
relapse. As these variables were deemed independent, we
investigated whether pARS515 expression could inform on patients
with PSA p20 ngml 1 at diagnosis. These patients, within each
individual clinical context, are considered as suitable for immediate
or delayed radical treatment (via active surveillance). Many of these
patients will have indolent disease that may never reach clinical
consequence and therefore are at risk of over-treatment. In
contrast, a subset have occult aggressive tumours that will progress
if treatment is delayed. Therefore, biomarkers to aid treatment
decision-making in this group of patients would have important
clinical implications. When patients with PSA at diagnosis
p20 ngml 1 were stratified by cytoplasmic pARS515 expression,
those tumours with high expression had significantly shorter time
to biochemical relapse than those patients with low expression
(P¼ 0.019) (Figure 2A). This translated into significantly shorter
Table 4. Associations between candidate kinases and androgen receptor phosphorylation sites
Candidate kinases
Cdk1 pCdk1
161
pERK1/2
AR phosphorylation sites Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total Cytoplasmic Nuclear Total
Ser-81
Cytoplasmic
CC 0.545 0.208 0.509 0.446 0.211 0.346 0.068  0.158 0.218
P-value o0.001 0.099 o0.001 0.001 0.134 0.012 0.61 0.231 0.113
Nuclear
CC 0.057 0.569 0.439 0.185 0.278 0.305 0.019 0.003 0.014
P-value 0.657 o0.001 o0.001 0.190 0.046 0.028 0.886 0.979 0.918
Total
CC 0.300 0.500 0.552 0.345 0.297 0.382 0.019  0.072 0.218
P-value 0.016 o0.001 o0.001 0.012 0.032 0.005 0.888 0.586 0.113
Ser-515
Cytoplasmic
CC 0.273 0.025 0.167 0.455 0.008 0.172 0.051 0.061 0.074
P-value 0.025 0.843 0.178 o0.001 0.954 0.210 0.706 0.649 0.583
Nuclear
CC 0.181 0.532 0.507 0.105 0.558 0.531 0.098 0.038  0.029
P-value 0.143 o0.001 o0.001 0.444 o0.001 o0.001 0.464 0.780 0.831
Total
CC 0.275 0.457 0.167 0.297 0.500 0.549 0.061 0.060 0.009
P-value 0.024 o0.001 o0.001 0.028 o0.001 o0.001 0.648 0.656 0.949
Abbreviation: AR¼ androgen receptor; CC¼Pearson’s correlation coefficients.
Values in bold denote associations with Pearson’s correlation co-efficient40.4 and P-valueo0.05.
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disease-specific survival (Po0.001, 10-year survival 38.1% vs
100%) (Figure 2B).
AR agonists stimulate Cdk1 and AR phosphorylation. In the
clinical specimens, pARS81 and pARS515 were demonstrated to
correlate with pCdk1161. In vitro, it was observed by western blot
analysis that the androgen DHT could induce phosphorylation of
Cdk1161, ARS81 and ARS515, with AR and Cdk1 expression levels
remaining constant (Figure 3). Analysis of paraffin-embedded cell
pellets confirmed the observation that treatment with DHT
stimulates phosphorylation at pCdk1161, pARS81 and pARS515
(Figure 4). As shown in Figure 4, it was demonstrated that DHT
stimulated cellular proliferation, as assessed by Ki67. In addition,
treatment with a Cdk inhibitor, Roscovitine, markedly decreased
basal expression of pCdk1161, pARS81, pARS515 and cell prolifera-
tion (Figure 4).
DISCUSSION
The current study suggests that in vitro activation of Cdk1 may be
associated with phosphorylation of AR at Serine 81 and Serine 515,
and thereby induce cellular proliferation. In addition, this
association was also observed in the clinical specimens with
pARS515 expression observed to be a negative prognostic marker,
independent of known clinical parameters.
Contrary to previous reports, pERK1/2 did not correlate with
any of the AR phosphorylation sites predicted by Scansite
(Anderson et al, 1990). In addition, pERK1/2 was not associated
with any clinical outcome measures. We have previously reported
that ERK1/2 is a negative prognostic marker in castrate-resistant
prostate cancer; therefore, activation of the ERK1/2 pathway may
be a late event and not associated with hormone-naive disease
(Mukherjee et al, 2011). In support of this hypothesis, it was
previously reported that ERK1/2 expression was low or undetect-
able in the majority of prostate cancer specimens at diagnosis,
however increased with stage, Gleason grade and progression to
castrate-resistant disease (Gioeli et al, 2006). In our patient cohort,
phosphorylated ERK1/2 was not associated with Gleason grade and
we postulate that disease progression may occur via other indirect
mechanisms such as phosphorylation of the AR co-activator
steroid receptor cofactor 1, and increasing cellular proliferation
through AP-1, c-MYC, and NF-kB (Bakin et al, 2003; Bell et al,
2003; Fu et al, 2003; Powell et al, 2004).
In the current study, we were surprised to observe that
phosphorylated AR expression in the cytoplasm was a stronger
prognostic factor than nuclear expression. However, presence of
cytoplasmic AR is expected as the AR localises to the cytoplasm in
the absence of ligand binding due to a ligand-regulated nuclear
export signal (Tyagi et al, 2000; Wen et al, 2000). We suggest that
immunohistochemical detection of cytoplasmic AR is an adverse
prognostic feature as it may indicate high levels of nuclear receptor,
as was the case with glucocorticoid receptors (McCarty et al, 1986).
In support of this notion, AR expression and phosphorylation
strongly correlated between the cytoplasm and nucleus in our
study (results not shown) and high cytoplasmic pARS515 expression
was associated with worse clinical outcome. This is not the first
study to observe that cytoplasmic AR expression is a stronger
prognostic factor that nuclear expression, cytoplasmic AR expres-
sion in patients with negative surgical margins after radical
prostatectomy was associated with worse prognosis (Diallo et al,
2008). Furthermore, the expression of cytoplasmic AR increased
with the progression of prostate intraepithelial neoplasia to
prostate cancer and from hormone-naive to castrate-resistant
cancer (Diallo et al, 2008). In addition, the subcellular location and
activity of AR is likely to be influenced by its phosphorylation
status. We propose that differential phosphorylation of the AR as it
shuttles between the nucleus and cytoplasm may be a more gradual
process, allowing detection of phosphorylated residues in both
cellular compartments by IHC. Alternatively, the kinases mediating
AR phosphorylation at these residues may be dysregulated in
malignant human prostate tissue, causing their localisation and
activity not to be confined to a single compartment.
Notwithstanding these differences in the reported subcellular
location of the AR and phosphorylated AR, our results suggest that
Cdk1 may phosphorylate multiple serine sites on the AR and
demonstrate that they are of clinical significance in prostate cancer.
In broad agreement with predictions by Scansite, phosphorylation
of all putative Ser-Pro target sites on the AR correlated significantly
with the expression of Cdk1 but not ERK1/2 in at least one cellular
Table 5. Relationship between kinases and androgen receptor with
clinical outcome measures
Time to
biochemical
relapse
Survival from
biochemical
relapse
Disease-
specific
survival
AR cytoplasm 0.466 0.922 0.517
AR nucleus 0.001 0.688 0.233
AR total o0.001 0.711 0.580
pARS81 cytoplasm 0.166 0.578 0.057
pARS81 nucleus 0.594 0.407 0.031
pARS81 total 0.925 0.383 0.039
pARS94 cytoplasm 0.927 0.793 0.864
pARS94 nucleus 0.375 0.202 0.991
pARS94 total 0.178 0.425 0.884
pARS308 cytoplasm 0.255 0.423 0.423
pARS308 nucleus 0.974 0.634 0.628
pARS308 total 0.685 0.275 0.297
pARS515 cytoplasm 0.020 0.016 o0.001
pARS515 nucleus 0.877 0.189 0.072
pARS515 total 0.708 0.216 0.034
pARS650 cytoplasm 0.977 0.431 0.113
pARS650 nucleus 0.909 0.229 0.177
pARS650 total 0.530 0.342 0.059
Cdk1 cytoplasm 0.988 0.011 0.007
Cdk1 nucleus 0.791 0.624 0.434
Cdk1 total 0.827 0.337 0.134
pCdk1161 cytoplasm 0.396 0.356 0.013
pCdk1161 nucleus 0.889 0.026 0.001
pCdk1161 total 0.166 0.413 0.007
pERK1/2 cytoplasm 0.353 0.188 0.668
pERK1/2 nucleus 0.384 0.207 0.509
pERK1/2 total 0.525 0.487 0.973
Abbreviations: AR¼ androgen receptor; CC¼Pearson’s correlation coefficients;
PSA¼prostate-specific antigen.
The proteins were grouped as pmedian or 4median and analysed by Kaplan–Meier
methods with reference to clinical outcome measures as shown.
Patients were considered to have biochemical relapse dependent on treatment; radical
prostatectomy serum PSA 40.2 ngml 1, radical radiotherapy serum PSA of 2.0 ngml 1
above the post-treatment nadir level, hormone treatment 2–3 consecutive rises in serum
PSA levels above the nadir obtained at intervals of 42 weeks (Roach et al, 2006; Cookson
et al, 2007).
Numbers in bold denote significant associations with P-value o0.05.
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location (Obenauer et al, 2003). Our study suggests that Cdk1 may
drive phosphorylation of multiple serine sites on the AR. As Cdk1
expression correlated more strongly with certain phosphorylation
sites, it may be that some sites are preferentially phosphorylated
by related kinases, such as Cdk11 or Cdk7 (Zong et al, 2007;
Chymkowitch et al, 2011). Not only did phosphorylation of the AR
at predicted serine sites correlate with Cdk1 and pCdk1161, both
Cdk1 and pCdk1161 were also strongly associated with clinical
outcome measures. The association of Cdk1 expression in radical
prostatectomy specimens with prostate cancer recurrence has been
reported previously (Kallakury et al, 1997). Our study has added to
this by observing that high expression of Cdk1, pCdk1161 and
phosphorylation of the putative Cdk1-consensus site pARS515 was
associated with decreased survival from biochemical relapse and, in
addition to pARS81, disease-specific survival. These results suggest
that phosphorylation of the AR by Cdk1 may be of functional
importance.
Through the use of a Cdk inhibitor, we observed that pARS81
and pARS515 expression is mediated, at least in part, by Cdk1.
Previous work has suggested that increased Cdk1 activity is a
mechanism for increasing AR expression, stability and cellular
proliferation (Chen et al, 2006). In the current study although we
observed an increase in Cdk1 phosphorylation AR expression
remained stable, however, change in expression might take place
over a longer time frame than investigated in the current study. We
therefore consider that another role of Cdk1, out-with cell-cycle
progression, is AR phosphorylation (in particular at serine 515).
Thus, Cdk1 may provide a mechanism for accelerating disease
progression in hormone-naive prostate cancer and a novel point
for therapeutic intervention. Future work would consist of Cdk1
knockdown via cell silencing experiments to clarify the precise
nature of the Cdk1/AR axis.
Ser-81 is the most frequently phosphorylated site on AR in
response to androgen binding (Chen et al, 2006). However,
pARS515 was found to be independent of current clinical para-
meters ahead of pARS81. This is in line with previous work which
demonstrated that abolishment of pARS81 in cell lines did not alter
androgen-dependent AR transcriptional activity, rapidly induced
AR-regulated genes or AR stabilisation mediated by Cdk1 (Chen
et al, 2006). In contrast, similar removal of pARS515 resulted in
reduction of AR transcriptional activity in response to androgens
(Ponguta et al, 2008). Our study provides additional evidence to
support the hypothesis that site-specific AR phosphorylation is of
clinical importance in prostate cancer.
The phosphorylated AR antibodies were stringently validated
using western blot and peptide competition assays. We acknowl-
edge the possibility of cross-reactivity in the usage of phospho-
specific antibodies particularly on a protein such as AR with
multiple phosphorylation sites. To follow on from the current
study, we intend to validate these findings in a larger independent
patient cohort. Before commencing these studies additional
antibody validation will be performed via site-directed mutagenesis
followed by IHC of cell pellets to establish with absolute certainty
that the results observed are due to the individual phosphorylation
sites.
An obvious limitation of this study is the small sample size and
as such the results should be interpreted with caution and validated
in a large independent cohort. However, even with low patient
numbers, we have demonstrated that AR phosphorylation by Cdk1
at serine 515 can predict time to biochemical relapse in prostate
cancer patients with PSA p20 ngml 1. Within this group of
patients, 10-year disease-specific survival was 100% in those
patients with low pARS515 expression compared with 38% in those
with high expression. These results are striking in particular when
considered that this was a hormone-naive cohort of patients who
subsequently received a variety of treatments (surgery, radio-
therapy and hormones) and that, due to small numbers, we were
unable to unpick these groups. We now intend to pursue this work
in a cohort of patients treated initially by active surveillance.
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Figure 2. (A) Kaplan–Meier survival plot showing time to biochemical relapse in patients with PSA p20ngml 1 at diagnosis (n¼28) stratified
according to low (solid line) and high (dashed line) cytoplasmic pARS515 expression. (B) Kaplan–Meier survival plot showing disease-specific survival
in patients with PSA p20ngml1 at diagnosis (n¼28) stratified according to low (solid line) and high (dashed line) cytoplasmic pARS515
expression.
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Figure 3.Western blot was performed on 50mg of extracts from LNCaP
cells treated with 10 nM dihydrotestosterone (DHT) for various lengths
of time as shown. Cdk1 is known to have an isomer called CDC2deltaT
that lacks 171 nucleotides corresponding to 57 amino acids, which
compose most of the T-loop (Ohta et al, 1998). CDC2deltaT has been
identified in breast cancer tissue, and currently there is no evidence for
this in prostate cancer but it may account for the duplex band seen in
Cdk1 and pCdk1161.
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This study suggests that Cdk1 may phosphorylate AR at serine
81 and serine 515, thereby driving cellular proliferation. In
combination with current diagnostic tools, pARS515could provide
a desperately needed prognostic marker to aid treatment decision-
making in prostate cancer patients with PSA p20 ngml 1 at
diagnosis. This finding has the potential to reduce over-treatment
of clinically insignificant disease and prevent delay in treatment of
occult aggressive disease. Overall morbidity and mortality suffered
by prostate cancer patients would be drastically reduced.
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